Connect.Parkinson national research study achieves enrollment target

NewsGuard 100/100 Score

The National Parkinson Foundation (NPF) announced today that the Connect.Parkinson national research study, comparing telemedicine care delivered to remote patients from a Parkinson's disease center of excellence to community-based care for Parkinson's disease, has achieved its enrollment target. The 200 enrolled participants with Parkinson's from across the country will be randomly assigned to continue their usual care, or to continue their usual care and see a Parkinson's expert via Internet video calls over the course of one year.

Connect.Parkinson is conducted by the University of Rochester, in collaboration with NPF, and is supported through a Patient-Centered Outcomes Research Institute (PCORI) award. This is the first nation-wide randomized, controlled clinical trial of telemedicine for Parkinson's and among the first national clinical trial of telemedicine that seeks to deliver care from a specialist to a patient directly in her home. Through NPF's Centers of Excellence network, Peter Schmidt, PhD, Senior Vice President and Chief Mission Officer was able to provide a national network of expert care for the study.

"Expert Parkinson's care has the potential to save 7,000 lives each year. However, for many patients today, access to expert care is difficult and time consuming. We are working to change the paradigm and demonstrate that the highest quality care can be delivered anywhere," said Dr. Schmidt.

The study team is led by Ray Dorsey, MD, a thought leader in digital health, who is announcing the completion of enrollment at the d.Health Summit 2015 in New York City on Friday, May 29. The summit provides a platform for national leaders in public policy, healthcare, finance and the high-tech industry to assemble for a day-long discussion on disruptive care models for aging Americans.

"We are excited by the overwhelming interest and completion of enrollment in the Connect.Parkinson study. Over 1000 individuals with Parkinson's disease and their families expressed interest in participating in the study, which speaks to the large latent demand for the next generation house call," said Dr. Dorsey, Professor of Neurology at the University of Rochester Medical Center. "We thank PCORI, NPF, our partners, the sites, and the participants for all of their efforts to date. We look forward to the successful completion of the study and moving us closer to enabling anyone anywhere with Parkinson's disease to receive care."

As chronic conditions affect an estimated 140 million Americans and account for more than 75 percent of healthcare spending today, the goal of the study is to demonstrate the effectiveness of using video technology in care for patients. Once scaled, this effort could bring together the country's leading healthcare organizations and potentially transform care in unprecedented ways.

"It's one thing to show how one highly-skilled doctor can deliver effective care at a distance, as Dr. Dorsey has done in previous studies. It's quite another to show how the same quality can be achieved with a network of providers at the scale of this study," said Christopher Herot, Chief Executive Officer of SBR Health.

Additional partners in the study include SBR Health, Vidyo, IDSolutions, and PatientsLikeMe.

The Connect.Parkinson study is part of NPF's broader mission to improve the quality of care and to improve access to care for people living with Parkinson's.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research validates anti-inflammatory properties of wine using urinary tartaric acid as biomarker